Takeda Tests TAK-510 Safety in First Human Trial for Nausea and Vomiting
Takeda's Phase 1 trial evaluates the safety and tolerability of TAK-510, a novel injectable agent targeting nausea and vomiting, across escalating doses.
Summary
TAK-510 is a novel investigational drug developed by Takeda to address nausea and vomiting. This completed Phase 1 trial enrolled healthy adult volunteers to assess safety, tolerability, and the maximum dose that can be administered without significant side effects. The study was structured in three parts, each testing single or multiple daily subcutaneous injections of TAK-510 at progressively higher doses compared to placebo. Participants were monitored in-clinic for several days post-injection, with follow-up visits extending up to three weeks after treatment. While TAK-510's precise mechanism remains undisclosed in the abstract, the trial represents a foundational step in establishing the drug's safety profile before any patient-facing efficacy studies can proceed. Results have not yet been publicly reported in detail.
Detailed Summary
Nausea and vomiting remain among the most common and debilitating symptoms encountered across a wide range of medical conditions, from chemotherapy-induced illness to postoperative recovery and chronic gastrointestinal disorders. Despite existing antiemetic options, unmet need persists, driving the search for novel therapeutic agents. TAK-510, developed by Takeda, represents one such candidate, and this Phase 1 trial marks its first evaluation in human subjects.
The study enrolled healthy adult volunteers in a randomized, placebo-controlled, dose-escalation design. Participants were divided into three cohorts corresponding to three study parts. Part 1 involved a single subcutaneous injection; Part 2 involved once-daily injections for five consecutive days; Part 3 involved once-daily injections for seven days followed by a single booster injection one week later. All participants received either TAK-510 or a matching placebo, with doses ranging from lower to higher levels within each cohort.
The primary objectives focused on safety and tolerability — specifically identifying adverse events and determining the maximum tolerated dose. Pharmacokinetic assessments were likely also conducted during in-clinic monitoring periods, which ranged from four to nine days depending on the study part. Post-treatment follow-up occurred weekly for up to three weeks.
The clinical significance of TAK-510 lies in its potential as a new antiemetic option, particularly if it demonstrates a favorable safety profile and novel mechanism of action. For clinicians managing patients with refractory nausea or those intolerant of existing agents, new options could meaningfully improve quality of life.
However, the trial's scope is inherently limited. As a Phase 1 study in healthy volunteers, it cannot speak to efficacy, and no detailed results have been published beyond the registry listing. TAK-510's mechanism, structure, and therapeutic niche remain publicly undisclosed, making broader interpretation difficult at this stage.
Key Findings
- Phase 1 trial tested TAK-510 via subcutaneous injection across single-dose and multi-day dosing regimens in healthy adults.
- Three-part dose-escalation design aimed to identify the maximum tolerated dose without significant side effects.
- Study included up to 7 consecutive daily injections followed by a booster dose one week later in Part 3.
- All participants received post-treatment follow-up monitoring for up to 3 weeks after completing dosing.
- No efficacy data are available; this trial was designed solely to establish TAK-510's safety profile.
Methodology
This was a randomized, placebo-controlled, Phase 1 dose-escalation trial in healthy adult volunteers conducted across three sequential cohorts. Each part evaluated increasing doses of subcutaneous TAK-510 versus placebo, with in-clinic monitoring periods of 4–9 days and up to 3 weeks of post-treatment follow-up. The trial was sponsored by Takeda and registered on ClinicalTrials.gov (NCT04731922).
Study Limitations
This summary is based on the abstract and ClinicalTrials.gov registry entry only; full safety and pharmacokinetic results have not been publicly reported. TAK-510's mechanism of action, molecular class, and target indication beyond general nausea/vomiting remain undisclosed. As a Phase 1 healthy volunteer study, no conclusions about efficacy or real-world clinical utility can be drawn.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.